Navigation Links
Kosan Presents Updated Data on Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma at Ash
Date:12/8/2007

ompare three different dose groups of tanespimycin (50, 175 and 340 mg/m2), each in combination with bortezomib (1.3 mg/m2). Eligible patients must have failed three prior multiple myeloma regimens, including one each of bortezomib and lenalidomide (Revlimid(R)). The primary endpoint is objective response rate.

TIME-1 is designed as a Phase 3 trial in patients with disease relapse following a single prior course of treatment (first-relapse). TIME-1 is planned to be a randomized, open-label, multi-center international trial with a primary endpoint of progression free survival (PFS), comparing two groups: patients treated with bortezomib plus tanespimycin (dosed at 340 mg/m2) and patients treated with bortezomib alone. The primary endpoint is designed to be progression-free survival.

About Kosan

Kosan Biosciences is a biotechnology company advancing two new classes of anticancer agents through clinical development -- Hsp90 (heat shock protein 90) inhibitors and epothilones. Kosan is leveraging its proprietary discovery platform to generate a pipeline of potentially significant product candidates, primarily in the area of oncology.

Hsp90 inhibitors have a novel mechanism of action targeting multiple pathways involved in cancer cell growth and survival. Tanespimycin (KOS-953) is being tested in combination with bortezomib (Velcade(R)) in patients with multiple myeloma in a registration program called TIME. Tanespimycin is also being studied in HER2-positive metastatic breast cancer in combination with trastuzumab (Herceptin(R)), and as monotherapy in metastatic melanoma. Intravenous and oral formulations of Kosan's second-generation Hsp90 inhibitor, alvespimycin (KOS-1022), are being evaluated in Phase 1 clinical trials in hematologic and solid tumors and in HER2-positive metastatic breast cancer.

Epothilones inhibit cell division through a mechanism of action similar to taxanes, one of the most successful classes of anti-tumor agents.
'/>"/>

SOURCE Kosan Biosciences Incorporated
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. Kosans Motilin Receptor Agonist, Licensed to Pfizer, Enters Phase 1 Clinical Trial in Gastroesophageal Reflux Disease
2. Kosan Opens Registration Program for Lead Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma
3. Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
4. Kosans Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial
5. Kosan Presents Phase 1 Data Showing Antitumor Activity and Safety Profile of Epothilone KOS-1584 at AACR/NCI/EORTC Meeting
6. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
7. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
8. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
9. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
10. CEL-SCI Presents Data for CEL-1000 as a Vaccine Adjuvant with Recombinant Hepatitis B Virus Protein
11. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2009)... Ill., Dec. 15 Fenwal Inc., a ... collection, separation, safety and availability, announced today that ... Fenwal approval to market InterSol ® platelet ... solution is a specialized product used in ... a vital blood component used to prevent or ...
(Date:12/15/2009)... -- ,, Reportlinker.com announces that a new ... catalogue: ,, Hepatitis B Vaccines - ... ,, http://www.reportlinker.com/p0167309/Hepatitis-B-Vaccines---Pipeline-Analysis-and-Market-Forecasts-to-2015.html ,, Hepatitis ... Forecasts to 2015 ,, Summary ... report, "Hepatitis B Vaccines - Pipeline Analysis ...
(Date:12/15/2009)... Reportlinker.com announces that a ... in its catalogue: ,, http://www.reportlinker.com/p0168192/Top-Ten-Worlds-Leading-Orthopedics-Companies.html ... the competitive environment is unquestionably one ... the task crucial to business survival, ... competitive intelligence is vital to the ...
Breaking Medicine Technology:Fenwal Receives FDA Approval for New Solution Used to Store Donated Blood Platelets 2Reportlinker Adds Hepatitis B Vaccines - Pipeline Analysis and Market Forecasts to 2015 2Reportlinker Adds Hepatitis B Vaccines - Pipeline Analysis and Market Forecasts to 2015 3Reportlinker Adds Hepatitis B Vaccines - Pipeline Analysis and Market Forecasts to 2015 4Reportlinker Adds Hepatitis B Vaccines - Pipeline Analysis and Market Forecasts to 2015 5Reportlinker Adds Hepatitis B Vaccines - Pipeline Analysis and Market Forecasts to 2015 6Reportlinker Adds Hepatitis B Vaccines - Pipeline Analysis and Market Forecasts to 2015 7Reportlinker Adds Top Ten World's Leading Orthopedics Companies 2Reportlinker Adds Top Ten World's Leading Orthopedics Companies 3Satellite Dialysis Opens New Center in San Leandro CA 61499 1Satellite Dialysis Opens New Center in San Leandro CA 61499 2Vivakor Inc Announces Stock Dividend 14870 1Vivakor Inc Announces Stock Dividend 14870 2Vivakor Inc Announces Stock Dividend 14870 3Vivakor Inc Announces Stock Dividend 14870 4Forensic Scientists at Kansas City Crime Lab Release Validation Report Confirming Zygems forensicGEM 28R 29 Kit is a Reliable Rapid Method for Extrac 14868 1Forensic Scientists at Kansas City Crime Lab Release Validation Report Confirming Zygems forensicGEM 28R 29 Kit is a Reliable Rapid Method for Extrac 14868 2Forensic Scientists at Kansas City Crime Lab Release Validation Report Confirming Zygems forensicGEM 28R 29 Kit is a Reliable Rapid Method for Extrac 14868 3Forensic Scientists at Kansas City Crime Lab Release Validation Report Confirming Zygems forensicGEM 28R 29 Kit is a Reliable Rapid Method for Extrac 14868 4
... be placed in the brain to treat a stroke as ... Annual International Symposium on Endovascular Therapy (ISET).Stents have long been ... to prevent heart attacks and in the neck to prevent ... to treat occurring heart attacks by opening up the blocked ...
... the international,investment house specialising in medical sciences, said ... pioneering stem cell treatments if it is,to remain ... Professor Sir Christopher Evans, founder ... plc has received approval from the UK,Medicines and ...
Other Medicine Technology:Stents Can Treat - Not Just Prevent - Strokes, Suggests Early Research 2Stents Can Treat - Not Just Prevent - Strokes, Suggests Early Research 3UK Must Maintain its Momentum in Stem Cell Expertise 2
(Date:12/16/2009)... Socks and Insoles Awarded American Podiatric Medical Association’s Seal of ... ... December 15, 2009 -- As shoppers continue their search for ... green” and shop for items that are considered healthy for ... earth-friendly footwear products, many of today’s most stylish items are ...
(Date:12/16/2009)... development of products that help survivors of stroke and other ... publication of an interview with the inventors of their brand ... Therapy and Rehab Medicine, vol. 20, issue 20, page 26, ... ... (PRWEB) December 16, 2009 -- In the publication, ...
(Date:12/16/2009)... and what would be the perfect gift to give that special ... Beauty Engineer® and Licensed Esthetician Mary Schook introduces exceptional beauty products ... their best! , ... (PRWEB) December 16, 2009 -- ... a person get that special woman who has everything? Why stem ...
(Date:12/15/2009)... a new electrophoretic method for detecting MIRCERA and ... technique, using SARCOSYL-PAGE, has specifically enhanced sensitivity for ... of SDS-PAGE for detecting other EPOs. Details ... the World Anti-Doping Agency (WADA), appear in the ... published by Wiley-Blackwell. , MIRCERA (methoxy polyethylene ...
(Date:12/15/2009)... Consumer Watchdog Calls For Preserving State Authority, Ban ... ,, WASHINGTON, Dec. 15 Consumer ... provision for those over 55 and the public ... But the group said that the Senate must ... weakened bill to prevent ceding the entire health ...
Breaking Medicine News(10 mins):Health News:Put Some "Green" Into Gift-Giving With Eco-Friendly Footwear Products 2Health News:Put Some "Green" Into Gift-Giving With Eco-Friendly Footwear Products 3Health News:Put Some "Green" Into Gift-Giving With Eco-Friendly Footwear Products 4Health News:New Tailwind Device Improves Arm Function in Stroke Survivors with Paralysis 2Health News:New Online Beauty Store Suggests Stem Cells for the Woman Who Has Everything 2Health News:Researchers discover novel method for detecting MIRCERA 2Health News:The 'Big 3' Fixes for the Weakened Senate Health Reform Bill to Block Full Insurance Co. Take-Over of Health System 2Health News:The 'Big 3' Fixes for the Weakened Senate Health Reform Bill to Block Full Insurance Co. Take-Over of Health System 3Health News:The 'Big 3' Fixes for the Weakened Senate Health Reform Bill to Block Full Insurance Co. Take-Over of Health System 4Health News:The 'Big 3' Fixes for the Weakened Senate Health Reform Bill to Block Full Insurance Co. Take-Over of Health System 5
... the Proceedings for the 2003 Annual Meeting of the American ... be a more effective means of cancer prognosis than measuring ... woman’s diet. None of the measures for detecting breast cancer ... University of Texas.// ,But, he says that levels ...
... study of patients with viral encephalitis by researchers ... condition could cause seriouys movement,problems. The investigators studied ... whom had West Nile virus. They found that ... care, while four developed severe movement disorders like,tremor, ...
... This respiratory diesease that can be fatal and threatens ... 1485 cases have been identified worldwide with more than ... Italian doctor who discovered this illness recently succumbed to ... expert on communicable diseases woking for WHO , ,was ...
... detecting upper urinary tract transitional cell carcinoma by a ... checks for fibrinogen/fibrin degradation products. It appears to be ... cytology. The Researchers compared the efficacy of two types ... the diagnosis// of transitional cell carcinoma in patients with ...
... approved a new patch developed by Watson Pharmaceuticals Inc., ... called Oxytrol (generic: oxybutynin transdermal system) reduces urinary urge ... drug's maker. Oral forms of oxybutynin has been around ... popular with patients due to side effects like// dry ...
... condition of the bladder wall. It typically affects young ... Investigators are testing the bacteria Bacillus Calmette-Guerin(BCG), which from ... interstitial cystitis, by inserting six installations into the bladders ... of BCG// also showed that 60 percent of patients ...
Other Medicine News:
"Small" redefined for Holter recorders!...
The MYO-VAD is a novel cardiac support system with unique, life-saving features....
LOGIQ Book XP provides you the next generation performance in a compact platform....
The Rio Catheter is designed to simplify your intravascular interventions by removing thrombus and restoring epicardial flow to the procedure....
Medicine Products: